SG10202012434QA - Methods of treating pancreatic cancer - Google Patents

Methods of treating pancreatic cancer

Info

Publication number
SG10202012434QA
SG10202012434QA SG10202012434QA SG10202012434QA SG10202012434QA SG 10202012434Q A SG10202012434Q A SG 10202012434QA SG 10202012434Q A SG10202012434Q A SG 10202012434QA SG 10202012434Q A SG10202012434Q A SG 10202012434QA SG 10202012434Q A SG10202012434Q A SG 10202012434QA
Authority
SG
Singapore
Prior art keywords
methods
pancreatic cancer
treating pancreatic
treating
cancer
Prior art date
Application number
SG10202012434QA
Inventor
Petrus Bekker
Shichang Miao
Israel Charo
Tom Schall
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of SG10202012434QA publication Critical patent/SG10202012434QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202012434QA 2016-06-13 2017-06-13 Methods of treating pancreatic cancer SG10202012434QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349217P 2016-06-13 2016-06-13
US201662382689P 2016-09-01 2016-09-01

Publications (1)

Publication Number Publication Date
SG10202012434QA true SG10202012434QA (en) 2021-01-28

Family

ID=60663739

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202012434QA SG10202012434QA (en) 2016-06-13 2017-06-13 Methods of treating pancreatic cancer
SG11201810940XA SG11201810940XA (en) 2016-06-13 2017-06-13 Methods of treating pancreatic cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201810940XA SG11201810940XA (en) 2016-06-13 2017-06-13 Methods of treating pancreatic cancer

Country Status (14)

Country Link
EP (1) EP3468548B1 (en)
JP (3) JP7083214B2 (en)
KR (2) KR20230047210A (en)
CN (1) CN109562086A (en)
AU (1) AU2017283491B2 (en)
BR (1) BR112018075660A2 (en)
CA (1) CA3026515A1 (en)
ES (1) ES2895749T3 (en)
IL (1) IL263508B2 (en)
MX (1) MX2018015172A (en)
RU (1) RU2768479C2 (en)
SG (2) SG10202012434QA (en)
WO (1) WO2017218544A1 (en)
ZA (1) ZA201808258B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
KR20230047210A (en) * 2016-06-13 2023-04-06 케모센트릭스, 인크. Methods of treating pancreatic cancer
WO2020060247A1 (en) * 2018-09-19 2020-03-26 오토텔릭바이오 주식회사 Anticancer composition
TW202214287A (en) * 2020-08-24 2022-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Use of combination of tgf-β receptor fusion protein and multi-target tyrosine kinase inhibitor in preparation of medicine of tumor treatment
CN118103067A (en) * 2021-09-14 2024-05-28 信达生物制药(苏州)有限公司 Pharmaceutical combinations of anti-PD-1 antibodies and chemotherapeutic agents and methods of use thereof
CN115521913B (en) * 2022-02-22 2023-07-25 北京景达生物科技有限公司 NK cells and CD20, CD38 and Her2 antibodies combined application
CN116804221B (en) * 2023-08-23 2023-11-03 汲迈生命科技(苏州)有限公司 Application of LMO7 expression level in prediction of pancreatic cancer gemcitabine resistance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
MX2009005252A (en) * 2006-11-17 2009-05-28 Abbott Lab Aminopyrrolidines as chemokine receptor antagonists.
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
EP2175859B1 (en) * 2007-07-12 2012-03-07 ChemoCentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
EA020885B1 (en) * 2008-01-22 2015-02-27 Мерк Патент Гмбх Protein kinase inhibitors and use thereof
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
JP5632014B2 (en) * 2009-12-17 2014-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel CCR2 receptor antagonists and uses thereof
RU2627268C2 (en) * 2012-02-29 2017-08-04 Хемоцентрикс, Инк. Aza-aryl-1-h-pyrazol-1-yl-sulphonamides
JP6523337B2 (en) * 2014-05-05 2019-05-29 リセラ・コーポレイションLycera Corporation Benzenesulfonamides and related compounds for use as agonists of ROR.gamma. And disease treatment
KR20230047210A (en) * 2016-06-13 2023-04-06 케모센트릭스, 인크. Methods of treating pancreatic cancer

Also Published As

Publication number Publication date
RU2768479C2 (en) 2022-03-24
ES2895749T3 (en) 2022-02-22
RU2019100220A (en) 2020-07-15
SG11201810940XA (en) 2019-01-30
CA3026515A1 (en) 2017-12-21
IL263508B2 (en) 2023-06-01
JP7083214B2 (en) 2022-06-10
IL263508A (en) 2019-01-31
MX2018015172A (en) 2019-07-04
JP2020147602A (en) 2020-09-17
KR20230047210A (en) 2023-04-06
EP3468548B1 (en) 2021-08-04
CN109562086A (en) 2019-04-02
JP2019518038A (en) 2019-06-27
WO2017218544A1 (en) 2017-12-21
BR112018075660A2 (en) 2019-04-09
AU2017283491A1 (en) 2018-12-20
AU2017283491B2 (en) 2021-06-03
KR20190017913A (en) 2019-02-20
ZA201808258B (en) 2022-04-28
RU2019100220A3 (en) 2020-12-24
JP2020147601A (en) 2020-09-17
EP3468548A1 (en) 2019-04-17
EP3468548A4 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
HK1258098A1 (en) Methods of treating cancer
IL275663A (en) Methods of treating cancer
HK1251409A1 (en) Methods of treating cancer
IL269026A (en) Methods of treating tumor
ZA201804227B (en) Methods of treating cancer
IL263925A (en) Methods of treating ovarian cancer
IL262342A (en) Methods of treating cancer
ZA201808258B (en) Methods of treating pancreatic cancer
IL264443A (en) Methods of treating prostate cancer
HK1251927A1 (en) Novel biomarkers and methods of treating cancer
EP3325006A4 (en) Methods of treating cd166-expressing cancer
ZA201908539B (en) Method of treatment of cancer
EP3487999A4 (en) Methods of treating cancer
SG11202005163PA (en) Methods of treating cancer
IL267613A (en) Treatment of pancreatic cancer
GB201717945D0 (en) Method for treatment of cancer
EP3200801A4 (en) Methods of treating pancreatic cancer
IL269123A (en) Methods of treating cancer
IL272379A (en) Methods of treating cancer by inhibiting setd2
GB201510197D0 (en) Method of treating ovarian cancer
GB201702139D0 (en) Methods of cancer treatment
GB201604293D0 (en) Treatment of cancer
GB201507937D0 (en) Compounds for treatment of pancreatic cancer